Program TBVI symposium

We would like to share the (draft) program for the TBVI symposium 2024, which will be held on January 30 and 31, 2024 in Les Diablerets.

TBVI Symposium 2024 Tuesday January 30– Wednesday morning January 31

Tuesday January 30, 2024

14.00-14.05 – Welcome and Opening: (TBVI GB tbd), TBVI, The Netherlands

Fundamental and applied research and novel technologies to innovate the TB vaccine pipeline

Novel insights in mucosal vaccine administration and spatial-temporal patterns of the local immune response in and beyond TB (chair: Olivier Nyerolles)

14:05-14.10 – Introduction (Olivier Neyrolles)
14.10-14.30 – Brittany Hartwell [U Minnesota, Minneapolis]:
14.30-14.50 – David Schreiner [U Basel]:
14.50-15.10 – Emma Lefrancais [CNRS-IPBS Toulouse]: “Intravital imaging of lung immune responses”
15:10-15.25 – Young Scientist [Tbd]
15:25-15.45 – Klaas van Gisbergen, [Champalimaud, Portugal] “Immunological Memory of the Tissues”
15.45-16.05 – Discussion and Summary (All, Olivier Neyrolles)
16.05-16.35 – Coffee break

Novel TB vaccine candidates:
Innovative approaches, In vivo-/in vitro-models, tools and technologies (chair: Andrea Cooper)

16.35-16.40 – Introduction (Andrea Cooper)
16.40-17.00 – David Lewinsohn [OHS U Portland]:
17.00-17.20 – Björn Corleis [FLI Isle of Riems]: “Inter-species comparison of immune responses to novel mucosal vaccine concepts”
17.20-17.40 – Tom Scriba [SATVI Cape Town]: “Role of T cell repertoires in Mtb control vs. disease progression”
17.40-18.00 – Thomas Lindenstroem (SSI): “Vaccine-promoted HEVs and T cell trafficking in the Mtb infected lung”
18.00-18.15 – Juliane Huebner [TissUse Berlin]
18.15-18.30 – Helen McShane: “Controlled Human Infection Model (CHIM)”
18.30-18.40 – Discussion and Summary (All, Andrea Cooper)
18.40-18.45 – Overall wrap-up & summary, Outlook to Wednesday (Andrea & Olivier & TBVI repr.)

19.00-20.00 – Reception
20.00 Joint dinner

Wednesday January 31, 2024

08.00-08.05 – Welcome and programme of the day (Elly van Riet)

2. Accelerating Clinical Development

08.05-08.15 – Introduction (Helen McShane)
08.15-08.30 – Mark Hatherill [UCT South Africa] – Overview TB Vaccine Clinical Pipeline
08.30-08.45 – Carlos Martin [UNIZAR Spain] – MTBVAC
08.45-09.00 – Merce Armat [Archivel France] Title: RUTI®, a therapeutic vaccine to improve TB treatments. Update on recent clinical trials results.
09.00-09.15 – Sina Brueckner [SLS Europe]
09.15-09.30 – Young scientist
09.30-09.45 – Ann Ginsberg [BMGF US]
09.45-10.00 – Alvaro Borges [SSI Denmark]
10.00-10.30 – Coffee break
10.30-11.00 – Pragmatic design of efficacy trials

Interactive debate with Mark Hatherill and Frank Cobelens, moderated by Helen McShane

3. Enablers to ensure public health impact

11.00-11.15 – Debbie King [Wellcome Trust]
11.15-11.30 – Jean Marie Habarugira – [GH EDCTP3]
11.30-11.45 – Ann Ginsberg [BMGF]
11.45-12.00 – Young scientist
12.00-12.15 – Birgitte Giersing [WHO] “WHO activities to accelerate TB vaccine development and use”
12.15-12.30 – Summary and Closure (tbd)